发明授权
- 专利标题： Isoxazolines as inhibitors of fatty acid amide hydrolase
- 专利标题（中）： 异恶唑啉作为脂肪酸酰胺水解酶的抑制剂
-
申请号： US12782650申请日： 2010-05-18
-
公开(公告)号： US09149465B2公开(公告)日： 2015-10-06
- 发明人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
- 申请人： Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
- 申请人地址： US MA Cambridge
- 专利权人： Infinity Pharmaceuticals, Inc.
- 当前专利权人： Infinity Pharmaceuticals, Inc.
- 当前专利权人地址： US MA Cambridge
- 代理机构： Jones Day
- 主分类号： C07D261/04
- IPC分类号： C07D261/04 ; A61K31/5377 ; A61K31/42 ; A61K31/4245 ; A61K31/4439 ; A61K31/4709 ; A61K31/501 ; A61K31/506 ; C07D413/04 ; C07D413/12 ; C07D413/14 ; C07D471/04
摘要：
The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient.The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.
公开/授权文献
- US20110028478A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE 公开/授权日：2011-02-03